DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The "Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Plaque Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive insights about marketed and Phase III products for Plaque Psoriasis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Plaque Psoriasis marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' names along with their locations.

This report provides a comprehensive understanding of the emerging Phase III therapies for Plaque Psoriasis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Plaque Psoriasis: Overview

Risk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

Product Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities

5. Emerging Therapies (Phase III)

Product Description Research and Development Product Development Activities For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gngf3h/plaque_psoriasis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005445/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Psoriasis Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 02:41 PM/DISC: 09/07/2018 02:41 PM